SinglePass has announced the publication of a multicentre retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.
Percutaneous biopsy tract haemorrhage is among the most common complications of image-guided biopsy. The SinglePass device applies pinpoint cautery along the needle tract during withdrawal, addressing a bleeding risk that has been considered unavoidable. The multicentre data span liver, kidney, and lung cases.
“Biopsy tract haemorrhage has long been accepted as an inherent risk of our practice, but these data findings make clear that it doesn’t have to be,” said Alexander Misono, chief of Interventional Radiology at Hoag Health System in Orange County and study investigator. “Bleeding complications drive blood transfusions, overnight admissions, and delayed discharge, so 100% technical success and zero clinically significant bleeding events across Hoag’s multicentre cohort are highly impactful results.”
“SinglePass’s collaboration with CATALiST [Center for Accelerating Technology and Life Sciences Translation], Hoag’s biomedical innovation hub, is exactly the kind of collaborative innovation work that directly improves patient outcomes,” said Michael Brant-Zawadzki, vice president of Clinical Research Administration and CATALiST. “Our key aim is enabling clinical thought leaders like Misono and industry innovators like SinglePass to work side by side to speed patient access to the latest technological advancements.”
“This peer-reviewed JVIR publication represents our commitment to clinical evidence and improving patient safety and biopsy care. We are grateful to Misono and the Hoag team for their partnership in bringing this exciting data to the interventional radiology community and the patients they serve,” said John Zehren, chief executive officer of SinglePass.
